Outputs (2)

Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy (2017)
Journal Article
Oluwasanmi, A., Al-Shakarchi, W., Manzur, A., Aldebasi, M. H., Elsini, R. S., Albusair, M. K., …Hoskins, C. (2017). Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. Journal of Controlled Release, 355-364. https://doi.org/10.1016/j.jconrel.2017.09.027

Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer. Currently, the first line treatment, gemcitabine, is only effective in 23.8% of patients. To improve this, a thermally activated system was develop... Read More about Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.

Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor. (2013)
Journal Article
Fisher, N., Hilton-Bolt, T., G Edwards, M., J Haxton, K., McKenzie, M., Allin, S. M., & Richardson, A. (2014). Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor. ACS medicinal chemistry letters, 5(1), 34-39. https://doi.org/10.1021/ml4003106

Autotaxin is an extracellular phospholipase D that catalyzes the hydrolysis of lysophosphatidyl choline (LPC) to bioactive lipid lysophosphatidic acid (LPA). LPA has been implicated in many pathological processes relevant to cancer, including cell mi... Read More about Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor..